藥明生物(02269.HK)與南韓Boostimmune簽訂獨家研發服務合作備忘錄
藥明生物(02269.HK)宣布,與南韓生物技術公司就Boostimmune產品的研究和發現服務簽署合作備忘錄。
根據合作,藥明生物將成為Boostimmune獨家研發服務合作夥伴,支持Boostimmune開發不同類型的候選藥物,包括單克隆抗體、雙抗體抗體和重組蛋白。
Boostimmune致力於開發調節腫瘤免疫微環境的新一代癌症療法和抑制創新靶點的ADC。藥明生物首席執行官陳智勝表示,南韓生物技術產業正呈現蓬勃發展階段,對於粉末發現和開發服務的需求也日益增長,公司非常自豪為全球和亞太合作夥伴賦能,幫助加速他們的創新生物藥上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.